Avinger (NASDAQ:AVGR) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Avinger (NASDAQ:AVGR) in a report published on Thursday morning. The firm issued a hold rating on the medical device company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $5.00 price objective on shares of Avinger in a research report on Thursday, March 21st.

Avinger Price Performance

AVGR traded up $0.06 during midday trading on Thursday, hitting $3.90. 10,223 shares of the company traded hands, compared to its average volume of 13,949. The company’s 50-day moving average is $3.46 and its 200 day moving average is $3.28. Avinger has a 52 week low of $2.50 and a 52 week high of $18.00.

Avinger (NASDAQ:AVGR) last released its quarterly earnings data on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by ($4.57). The firm had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $2.52 million. As a group, analysts predict that Avinger will post -2.08 EPS for the current year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.